Effect of systemic administration of L-kynurenine on corticocerebral blood flow under normal and ischemic conditions of the brain in conscious rabbits

K. Sas, Klára Csete, L. Vécsei, J. Papp

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Kynurenic acid, the only known endogenous antagonist of the excitatory amino acid receptors, exerts neuroprotective effect in focal cerebral ischemia. Kynurenic acid poorly while its bioprecursor, L-kynurenine (L-KYN) completely crosses the blood-brain barrier. The aim of our study was to investigate the effect of intravenous L-KYN (0.3, 1, and 3 mg/kg) on the normal and the unilateral carotid artery occlusion induced ischemic corticocerebral blood flow (cCBF) measured by hydrogen polarography in conscious rabbits. Administration of L-KYN produced a significant increase in the normal cCBF; the peak values were recorded at the dose of 1 mg/kg (187% at 120 and 150 mins. respectively). The cCBF-improving effect of L-KYN was immediate and highly pronounced also in rabbits with carotid occlusion (peak value was 192% at 120 mins. at the dose of 1 mg/kg). Pretreatment with either atropine or Nω -nitro-L-arginine-methylester (L-NAME) prevented the L-KYN induced enhancement of the normal and the ischemic cCBF alike. It is suggested that the cCBF-increasing effect of L-KYN might be mediated by activation of cholinergic and nitric oxide pathways.

Original languageEnglish
Pages (from-to)403-409
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Volume42
Issue number3
DOIs
Publication statusPublished - Sep 1 2003

Fingerprint

Kynurenine
Cerebral Cortex
Rabbits
Brain
Kynurenic Acid
Polarography
NG-Nitroarginine Methyl Ester
Glutamate Receptors
Neuroprotective Agents
Brain Ischemia
Blood-Brain Barrier
Atropine
Carotid Arteries
Cholinergic Agents
Arginine
Hydrogen
Nitric Oxide

Keywords

  • Conscious rabbits
  • Corticocerebral blood flow
  • Hydrogen polarography
  • L-kynurenine

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

@article{c24590e9146446bc82a58a516bfb224b,
title = "Effect of systemic administration of L-kynurenine on corticocerebral blood flow under normal and ischemic conditions of the brain in conscious rabbits",
abstract = "Kynurenic acid, the only known endogenous antagonist of the excitatory amino acid receptors, exerts neuroprotective effect in focal cerebral ischemia. Kynurenic acid poorly while its bioprecursor, L-kynurenine (L-KYN) completely crosses the blood-brain barrier. The aim of our study was to investigate the effect of intravenous L-KYN (0.3, 1, and 3 mg/kg) on the normal and the unilateral carotid artery occlusion induced ischemic corticocerebral blood flow (cCBF) measured by hydrogen polarography in conscious rabbits. Administration of L-KYN produced a significant increase in the normal cCBF; the peak values were recorded at the dose of 1 mg/kg (187{\%} at 120 and 150 mins. respectively). The cCBF-improving effect of L-KYN was immediate and highly pronounced also in rabbits with carotid occlusion (peak value was 192{\%} at 120 mins. at the dose of 1 mg/kg). Pretreatment with either atropine or Nω -nitro-L-arginine-methylester (L-NAME) prevented the L-KYN induced enhancement of the normal and the ischemic cCBF alike. It is suggested that the cCBF-increasing effect of L-KYN might be mediated by activation of cholinergic and nitric oxide pathways.",
keywords = "Conscious rabbits, Corticocerebral blood flow, Hydrogen polarography, L-kynurenine",
author = "K. Sas and Kl{\'a}ra Csete and L. V{\'e}csei and J. Papp",
year = "2003",
month = "9",
day = "1",
doi = "10.1097/00005344-200309000-00012",
language = "English",
volume = "42",
pages = "403--409",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effect of systemic administration of L-kynurenine on corticocerebral blood flow under normal and ischemic conditions of the brain in conscious rabbits

AU - Sas, K.

AU - Csete, Klára

AU - Vécsei, L.

AU - Papp, J.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Kynurenic acid, the only known endogenous antagonist of the excitatory amino acid receptors, exerts neuroprotective effect in focal cerebral ischemia. Kynurenic acid poorly while its bioprecursor, L-kynurenine (L-KYN) completely crosses the blood-brain barrier. The aim of our study was to investigate the effect of intravenous L-KYN (0.3, 1, and 3 mg/kg) on the normal and the unilateral carotid artery occlusion induced ischemic corticocerebral blood flow (cCBF) measured by hydrogen polarography in conscious rabbits. Administration of L-KYN produced a significant increase in the normal cCBF; the peak values were recorded at the dose of 1 mg/kg (187% at 120 and 150 mins. respectively). The cCBF-improving effect of L-KYN was immediate and highly pronounced also in rabbits with carotid occlusion (peak value was 192% at 120 mins. at the dose of 1 mg/kg). Pretreatment with either atropine or Nω -nitro-L-arginine-methylester (L-NAME) prevented the L-KYN induced enhancement of the normal and the ischemic cCBF alike. It is suggested that the cCBF-increasing effect of L-KYN might be mediated by activation of cholinergic and nitric oxide pathways.

AB - Kynurenic acid, the only known endogenous antagonist of the excitatory amino acid receptors, exerts neuroprotective effect in focal cerebral ischemia. Kynurenic acid poorly while its bioprecursor, L-kynurenine (L-KYN) completely crosses the blood-brain barrier. The aim of our study was to investigate the effect of intravenous L-KYN (0.3, 1, and 3 mg/kg) on the normal and the unilateral carotid artery occlusion induced ischemic corticocerebral blood flow (cCBF) measured by hydrogen polarography in conscious rabbits. Administration of L-KYN produced a significant increase in the normal cCBF; the peak values were recorded at the dose of 1 mg/kg (187% at 120 and 150 mins. respectively). The cCBF-improving effect of L-KYN was immediate and highly pronounced also in rabbits with carotid occlusion (peak value was 192% at 120 mins. at the dose of 1 mg/kg). Pretreatment with either atropine or Nω -nitro-L-arginine-methylester (L-NAME) prevented the L-KYN induced enhancement of the normal and the ischemic cCBF alike. It is suggested that the cCBF-increasing effect of L-KYN might be mediated by activation of cholinergic and nitric oxide pathways.

KW - Conscious rabbits

KW - Corticocerebral blood flow

KW - Hydrogen polarography

KW - L-kynurenine

UR - http://www.scopus.com/inward/record.url?scp=0042839690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042839690&partnerID=8YFLogxK

U2 - 10.1097/00005344-200309000-00012

DO - 10.1097/00005344-200309000-00012

M3 - Article

C2 - 12960686

AN - SCOPUS:0042839690

VL - 42

SP - 403

EP - 409

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -